Sponsors
The bill accelerates government evaluation and rapid scale-up of medical countermeasures and opens new commercial solicitation channels, but it does so by expanding noncompetitive purchasing authorities and procurement constraints that can reduce competition, transparency, and raise ethical concerns.
Hospitals and patients benefit from faster evaluation and scale-up of medical countermeasures because HHS can buy tests, prototypes, animal models, and supplies for evaluation and transition proven prototypes into production more quickly.
Small businesses and commercial innovators gain greater opportunity to compete for government work because HHS may use competitive general solicitations to attract commercial products and services.
Taxpayers and Congress get increased oversight on very large awards because recipients over $100 million require a written efficacy determination and congressional notification.
Small businesses and potential new suppliers may face reduced opportunities because allowing follow-on production contracts without additional competition can favor initial participants and limit open procurement.
Taxpayers face greater risk of wasteful spending and reduced transparency when HHS makes noncompetitive purchases for experimental or test purposes.
Small businesses developing complex or uncertain R&D may be discouraged because competitive-general-solicitation awards limited to fixed-price contracts can deter projects needing flexible pricing or cost-reimbursement arrangements.
Based on analysis of 2 sections of legislative text.
Expands HHS prototype and acquisition authorities to permit testing/prototypes and models, allow follow-on noncompetitive production awards, authorize noncompetitive testing procurements, and create a limited competitive route for innovative commercial items.
Introduced January 28, 2025 by Robert Garcia · Last progress January 28, 2025
Expands HHS authority to speed development and acquisition of medical countermeasures and related supplies by clarifying that "design and development" includes tests, prototypes, and models; allowing prototype transactions to include follow-on production awards to participants without a new competition; permitting noncompetitive procurements for experimental or test purposes; and creating a competitive general-solicitation path for acquiring "innovative commercial" products and services with fixed-price limits, a $100 million cap unless justified, and congressional notification for very large awards. The changes aim to shorten timelines for moving prototypes into production and to provide flexible purchasing tools during research, testing, and emergencies while imposing some limits and oversight for high-value procurements.